CCL modules ready for high-power testing

RNS Number : 8026W

Advanced Oncotherapy PLC

24 August 2015

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

CCL modules ready for high-power testing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the two Coupled Cavity Linac ("CCL") modules are now ready for high-power testing at the Company's facility in Geneva.

These two modules will be tested at high power by using the Radio Frequency ("RF") Power Units provided by ScandiNova and Toshiba and it is the first time two CCL modules will be tested together. The finished LIGHT system will incorporate ten CCL units (15 CCL modules) in total and combined in a series will accelerate protons to the high energies required to treat radiosensitive tumours in a clinical setting.

Ensuring that the CCL units were ready for high-power testing was a key milestone in the Company's timetable provided to shareholders in November 2014, and this marks another successful stage in the process of delivering the first working LIGHT system.

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: "The high-power testing of the components at this stage will be a crucial demonstration of their ability to perform to specifications. Initial low power testing has shown that they perform to expectations and we expect that the successful conclusion of these tests will give us confidence that the CCL modules can work under the required conditions to deliver the high energy protons that we need to treat patients effectively."

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Jon Levinson / Zoe Alexander	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCPBMATMBITBBA